FREMONT, Calif., Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Cordis Corporation announced today the presentation of new data from the most recent clinical studies at the 2014 VEITHsymposium®, showcasing the company s diverse and strong endovascular technology portfolio. One of the featured Cordis podium presentations is the first-ever presentation of the three-year INCRAFT® AAA Stent Graft System (INCRAFT® System) Innovation study data.
Texas man is the world’s first to receive the PROTEK Duo for treatment following surgery
The Mediterranean diet is linked to improved cardiovascular performance in patients with erectile dysfunction, according to research presented at EuroEcho-Imaging 2014 by Dr Athanasios Angelis from Greece. Patients with erectile dysfunction who had poor adherence to the Mediterranean diet had more vascular and cardiac damage.
November 5, 2014—VIVA Physicians, Inc. announced that Eamon Dolan, MD, presented findings from the ROX-CONTROL HTN study during a late-breaking trials session at the VIVA 2014: Vascular InterVentional Advances meeting in Las Vegas, Nevada. The study is a randomized study evaluating the blood pressure-lowering effect of the Coupler device (Rox Medical, Inc.) in resistant hypertensive patients across European study sites.
October 30, 2014—RenovoRx announced that it has received US Food and Drug Administration 510(k) clearance of the RenovoCath RC120 catheter, which is designed for the isolation of blood flow and delivery of fluids, including diagnostic material and therapeutic agents, into selected sites in the peripheral vascular system utilizing a dual-balloon occlusion design.
October 27, 2014—Essential Medical, Inc. announced that it has received European CE Mark approval for its X-Seal vascular closure device. X-Seal closes femoral arterial punctures made during cardiac catheterization procedures such as angiograms, angioplasty, and stenting. The device is designed to provide catheterization lab professionals with superior closure and improved hemostasis, stated the company.
October 22, 2014—Gynesonics, Inc. announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the pivotal SONATA trial of sonography-guided transcervical ablation of uterine fibroids to evaluate the company’s VizAblate system. The VizAblate system is designed to provide a transcervical, incision-free, outpatient option to invasive surgical procedures, such as hysterectomy, for the relief of symptomatic uterine fibroids.
November 13, 2014—Covidien announced that the 6-month results of the VeClose pivotal study demonstrated the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The results were presented at ACP 2014, the American College of Phlebology’s annual congress, in Phoenix, Arizona.
November 12, 2014—The Society for Vascular Surgery (SVS) and Society of Interventional Radiology (SIR), on behalf of the Inferior Vena Cava (IVC) Filter Study Group Foundation, announced the planned 2015 commencement of the multicenter PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) study with the participation of seven IVC filter manufacturers. SVS and SIR collaboratively formed the IVC Filter Study Group Foundation, a 501(c)(3) not-for-profit entity that sponsors and oversees PRESERVE.
November 4, 2014—Cardinal Health announced that its MynxGrip vascular closure device received US Food and Drug Administration approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5-F, 6-F, and 7-F femoral arterial and femoral venous access sites. The MynxGrip device is intended to reduce times to hemostasis and ambulation, thereby potentially shortening postprocedure recovery times, stated the company.
The International Carotid Stenting Study (ICSS) randomised trial has reported the long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis in The Lancet, online ahead of print, on 14 October.
There is a compelling case for the medical community, including the device industry, to develop specific devices that are appropriate for paediatric patients. Paediatric interventional radiologists often have to “make do” and be creative in order to treat children whilst using devices that are designed for and tested on adults only. The need for appropriate devices for the paediatric population ranges from the common and simple, such as long-term feeding tubes and vascular access devices, to the expensive and biomechanically complex, such as bioabsorbable stent-grafts, say opinion leaders in the field.
The 12-month results of the study, presented at CIRSE 2014, demonstrated that new microwave technology can achieve a substantial rate of complete necrosis of liver metastases, even in a short-term treatment with few major complication
Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states
Ablative Solutions has announced that the first patient in the Peregrine Study has been treated with company’s the investigational Peregrine system, which delivers agents directly to the sympathetic-nerve-laden peri-adventitial area of the renal artery to perform chemical neurolysis. Wojtek Wojakowski is the principal investigator of the study, and the patient has now been discharged from the hospital
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos